Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAX NASDAQ:CLLS NASDAQ:IMCR NASDAQ:IMTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCAXBicara Therapeutics$22.33-2.6%$20.74$7.80▼$24.25$1.47B-0.57509,319 shs42,932 shsCLLSCellectis$4.06+1.9%$3.68$1.33▼$5.48$408.89M2.9441,115 shs1,467 shsIMCRImmunocore$29.07+0.8%$30.76$27.44▼$40.71$1.47B0.74421,403 shs15,557 shsIMTXImmatics$11.27-2.3%$10.41$4.15▼$12.41$1.51B1.31434,604 shs75,418 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCAXBicara Therapeutics+1.51%+5.77%+8.52%+53.11%+77.67%CLLSCellectis+3.38%+0.76%+10.86%+2.31%+148.75%IMCRImmunocore-2.47%+2.45%-7.09%-12.10%+1.58%IMTXImmatics+1.50%+6.95%+10.64%+16.21%+172.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCAXBicara Therapeutics$22.33-2.6%$20.74$7.80▼$24.25$1.47B-0.57509,319 shs42,932 shsCLLSCellectis$4.06+1.9%$3.68$1.33▼$5.48$408.89M2.9441,115 shs1,467 shsIMCRImmunocore$29.07+0.8%$30.76$27.44▼$40.71$1.47B0.74421,403 shs15,557 shsIMTXImmatics$11.27-2.3%$10.41$4.15▼$12.41$1.51B1.31434,604 shs75,418 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCAXBicara Therapeutics+1.51%+5.77%+8.52%+53.11%+77.67%CLLSCellectis+3.38%+0.76%+10.86%+2.31%+148.75%IMCRImmunocore-2.47%+2.45%-7.09%-12.10%+1.58%IMTXImmatics+1.50%+6.95%+10.64%+16.21%+172.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCAXBicara Therapeutics 2.69Moderate Buy$29.6032.58% UpsideCLLSCellectis 2.83Moderate Buy$6.7566.42% UpsideIMCRImmunocore 2.60Moderate Buy$57.7598.67% UpsideIMTXImmatics 2.67Moderate Buy$19.0068.59% UpsideCurrent Analyst Ratings BreakdownLatest CLLS, IMTX, BCAX, and IMCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026BCAXBicara Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$37.005/12/2026BCAXBicara Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$18.005/11/2026BCAXBicara Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$42.005/10/2026BCAXBicara Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/7/2026IMCRImmunocore Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Strong-Buy4/28/2026IMTXImmatics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/27/2026IMCRImmunocore Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/21/2026IMCRImmunocore Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CLLSCellectis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026IMCRImmunocore HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.004/14/2026CLLSCellectis Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$8.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCAXBicara TherapeuticsN/AN/AN/AN/A$7.33 per shareN/ACLLSCellectis$79.59M5.11N/AN/A$0.76 per share5.34IMCRImmunocore$412.81M3.57N/AN/A$7.52 per share3.87IMTXImmatics$54.60M27.67N/AN/A$4.09 per share2.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCAXBicara Therapeutics-$137.95M-$2.53N/AN/AN/AN/A-32.49%-30.87%N/ACLLSCellectis-$67.59M-$0.67N/AN/AN/A-84.92%-69.38%-19.51%7/30/2026 (Estimated)IMCRImmunocore-$35.51M-$0.55N/A264.26N/A-6.68%-7.07%-2.55%N/AIMTXImmatics-$222.26M-$1.84N/AN/AN/A-411.90%-41.81%-34.72%5/12/2026 (Estimated)Latest CLLS, IMTX, BCAX, and IMCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026IMTXImmatics-$0.42-$0.50-$0.08-$0.50$9.79 million$8.81 million5/11/2026Q1 2026BCAXBicara Therapeutics-$0.64-$0.93-$0.29-$0.93N/AN/A5/11/2026Q1 2026CLLSCellectis-$0.2583-$0.18+$0.0783-$0.18$11.04 millionN/A5/6/2026Q1 2026IMCRImmunocore-$0.26$0.25+$0.51$0.25$145.20 million$106.68 million3/30/2026Q4 2025BCAXBicara Therapeutics-$0.72-$0.68+$0.04-$0.68N/AN/A3/19/2026Q4 2025CLLSCellectis-$0.10-$0.26-$0.16-$0.26$10.74 million$15.50 million3/5/2026Q4 2025IMTXImmatics-$0.48-$0.34+$0.14-$0.34$12.18 million$23.18 million2/25/2026Q4 2025IMCRImmunocore-$0.28-$0.60-$0.32-$0.60$145.48 million$104.48 million2/14/2026Q4 2025IMCRImmunocoreN/A-$0.60N/A-$0.60N/A$104.48 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCAXBicara TherapeuticsN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCAXBicara TherapeuticsN/A14.5814.58CLLSCellectis0.981.621.62IMCRImmunocore1.004.184.15IMTXImmaticsN/A11.7211.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCAXBicara TherapeuticsN/ACLLSCellectis63.90%IMCRImmunocore84.50%IMTXImmatics64.41%Insider OwnershipCompanyInsider OwnershipBCAXBicara TherapeuticsN/ACLLSCellectis16.41%IMCRImmunocore10.40%IMTXImmaticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCAXBicara Therapeutics3265.60 millionN/AN/ACLLSCellectis290100.34 million83.87 millionOptionableIMCRImmunocore32050.70 million45.42 millionOptionableIMTXImmatics260134.07 millionN/AOptionableCLLS, IMTX, BCAX, and IMCR HeadlinesRecent News About These CompaniesImmatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates1 hour ago | zacks.comImmatics Announces First Quarter 2026 Financial Results and Business Update4 hours ago | globenewswire.comImmatics (IMTX) Expected to Announce Earnings on TuesdayMay 10 at 3:54 AM | americanbankingnews.comAll You Need to Know About Immatics (IMTX) Rating Upgrade to BuyMay 6, 2026 | zacks.comImmatics (IMTX) to Release Quarterly Earnings on TuesdayMay 5, 2026 | marketbeat.comImmatics (NASDAQ:IMTX) Rating Lowered to Sell at Wall Street ZenMay 2, 2026 | marketbeat.comTD Cowen initiates coverage of Immatics NV (IMTX) with buy recommendationApril 29, 2026 | msn.comImmatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual MeetingApril 21, 2026 | globenewswire.comPRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in ...April 19, 2026 | caledonianrecord.comCPRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic NephroblastomaApril 18, 2026 | markets.businessinsider.comImmatics N.V. (NASDAQ:IMTX) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 18, 2026 | marketbeat.comImmatics Phase 3 Progress Sharpens View On Anzu Cel Launch UpsideMarch 15, 2026 | finance.yahoo.comImmatics NV (IMTX) seeing strong enrollment in a key phase 3 trial of drug candidateMarch 13, 2026 | msn.comImmatics: Buying The Anzu-Cel Floor, Playing The Moderna MoonshotMarch 9, 2026 | seekingalpha.comImmatics Announces Full Year 2025 Financial Results and Business UpdateMarch 5, 2026 | markets.businessinsider.comImmatics: Q4 Earnings SnapshotMarch 5, 2026 | wtop.comWInstitutional investors own a significant stake of 38% in Immatics N.V. (NASDAQ:IMTX)January 15, 2026 | finance.yahoo.comBank of America Securities Reaffirms Their Buy Rating on Immatics (IMTX)January 12, 2026 | theglobeandmail.comImmatics price target raised to $17 from $14 at BofAJanuary 6, 2026 | msn.comImmatics (NASDAQ:IMTX) Stock Price Up 3.9% – Should You Buy?January 2, 2026 | defenseworld.netDImmatics: PRAME Leader's Transition To Commercial RealityDecember 25, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLLS, IMTX, BCAX, and IMCR Company DescriptionsBicara Therapeutics NASDAQ:BCAX$22.33 -0.59 (-2.59%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Cellectis NASDAQ:CLLS$4.06 +0.08 (+1.91%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Immunocore NASDAQ:IMCR$29.07 +0.22 (+0.76%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Immatics NASDAQ:IMTX$11.27 -0.27 (-2.34%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
